GlassScriptPhysician profile
Jeremy W Waters
NPI 1043536261
$2,724.00
in general payments reported to CMS, 2019-2025
25 companies · $61.54 in 2025
The $61.54 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,655 · 2020: $376 · 2021: $13.30 · 2022: $186 · 2023: $189 · 2024: $243 · 2025: $61.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $573.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $293.39 | 2019 | |
| Allergan, INC. | $288.48 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $272.41 | 2019-2020 | |
| Lilly USA, LLC | $255.26 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $207.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.73 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $137.61 | 2022-2023 | |
| Abbvie INC. | $97.57 | 2019-2024 | Linzess, Viberzi |
| Amarin Pharma, INC. | $76.64 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.13 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.69 | 2019 | |
| Avanir Pharmaceuticals, INC. | $28.48 | 2019 | |
| Abiomed | $25.33 | 2024 | Impella |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.88 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $19.29 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.91 | 2022 | |
| Bioventus LLC | $15.59 | 2019 | |
| Glaxosmithkline, LLC. | $14.90 | 2023 | Trelegy Ellipta |
| Ethicon US, LLC | $14.75 | 2019 | |
| Pfizer INC. | $13.07 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2.01 | 2025 | Lifevest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Waters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.